Open AccessOn the development of miransertib for rare diseases: an interview with ArQule's Brian Schwartz
Author(s) -
Brian Schwartz
Publication year - 2020
Publication title -
future drug discovery
Language(s) - English
Resource type - Journals
ISSN - 2631-3316
DOI - 10.4155/fdd-2019-0038
Subject(s) - drug development , biopharmaceutical , medicine , engineering ethics , pharmacology , drug , engineering , biology , genetics
Brian Schwartz is CMO of ArQule, a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for precision medicine oncology and rare diseases. In this interview he tells us more about the company's current projects, which include drug development for the rare diseases Proteus syndrome and PROS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom